Brands: Vyvanse · Lisdexamfetamine Dimesylate
Average across 97 priced NDCs. A benchmark of pharmacy acquisition cost - not a retail quote.
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume - Medicaid only, not all-payer.
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Bryant Ranch Prepack | repackager | 19 | SUPPLYING |
| Lannett Company, Inc. | generic | 7 | SUPPLYING |
| Teva Pharmaceuticals USA, Inc. | generic | 7 | SUPPLYING |
| Hikma Pharmaceuticals USA Inc. | generic | 7 | SUPPLYING |
| Sandoz Inc | generic | 7 | SUPPLYING |
| SpecGx LLC | unknown | 7 | SUPPLYING |
| Takeda Pharmaceuticals America, Inc. | unknown | 7 | SUPPLYING |
| SUN PHARMACEUTICAL INDUSTRIES, INC. | generic | 7 | SUPPLYING |
| Granules Pharmaceuticals Inc. | unknown | 7 | SUPPLYING |
| Camber Pharmaceuticals, Inc. | generic | 7 | SUPPLYING |
| Rhodes Pharmaceuticals LLC | unknown | 7 | SUPPLYING |
| Alvogen Inc. | unknown | 7 | SUPPLYING |
| Apotex Corp. | generic | 7 | SUPPLYING |
| Elite Laboratories, Inc. | unknown | 7 | SUPPLYING |
| American Health Packaging | repackager | 6 | SUPPLYING |
Shortages, recalls, and registration changes attached to this drug concept.
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate capsules. — Recalling firm: SUN PHARMACEUTICAL INDUSTRIES INC — U.S Nationwide.
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate capsules. — Recalling firm: SUN PHARMACEUTICAL INDUSTRIES INC — U.S Nationwide.
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate capsules. — Recalling firm: SUN PHARMACEUTICAL INDUSTRIES INC — U.S Nationwide.
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate capsules. — Recalling firm: SUN PHARMACEUTICAL INDUSTRIES INC — U.S Nationwide.
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate capsules. — Recalling firm: SUN PHARMACEUTICAL INDUSTRIES INC — U.S Nationwide.
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate capsules. — Recalling firm: SUN PHARMACEUTICAL INDUSTRIES INC — U.S Nationwide.
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate capsules. — Recalling firm: SUN PHARMACEUTICAL INDUSTRIES INC — U.S Nationwide.
Labeling: Label Mix-up. A bottle labeled as Lisdexamphetamine Dimesylate Capsules 40mg, contained Lisdexamphetamine Dimesylate Capsules 30mg. — Recalling firm: Lannett Company Inc. — Nationwide within the USA
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 9 month long term stability station (25¿C, 60%RH). — Recalling firm: SUN PHARMACEUTICAL INDUSTRIES INC — Recalled units were distributed to 17 distributors who may have further distributed the product nationwide.
Failed Content Uniformity Specifications: Product failed to meet the action limits for stratified content uniformity. — Recalling firm: Lannett Company Inc. — Nationwide in the USA
Lisdexamfetamine Dimesylate Capsule — reported in shortage by Apotex Corp.. Therapeutic category: Psychiatry.
Lisdexamfetamine Dimesylate Tablet, Chewable — reported in shortage by Takeda Pharmaceuticals USA Inc.. Therapeutic category: Psychiatry.
Lisdexamfetamine Dimesylate Capsule — reported in shortage by Teva Pharmaceuticals USA, Inc.. Therapeutic category: Psychiatry.
Lisdexamfetamine Dimesylate Capsule — reported in shortage by Lannett Company, Inc.. Therapeutic category: Psychiatry.
Lisdexamfetamine Dimesylate Capsule — reported in shortage by SpecGx LLC. Therapeutic category: Psychiatry.
Lisdexamfetamine Dimesylate Capsule — reported in shortage by Alvogen. Therapeutic category: Psychiatry.
Lisdexamfetamine Dimesylate Capsule — reported in shortage by Takeda Pharmaceuticals USA Inc.. Therapeutic category: Psychiatry.
Lisdexamfetamine Dimesylate Capsule — reported in shortage by Sun Pharmaceutical Industries, Inc.. Therapeutic category: Psychiatry.
Lisdexamfetamine Dimesylate Capsule — reported in shortage by Hikma Pharmaceuticals USA, Inc.. Therapeutic category: Psychiatry.
Lisdexamfetamine Dimesylate Capsule — reported in shortage by Rhodes Pharmaceuticals L.P.. Therapeutic category: Psychiatry.
Lisdexamfetamine Dimesylate Capsule — reported in shortage by Elite Laboratories, Inc.. Therapeutic category: Psychiatry.
Lisdexamfetamine Dimesylate Tablet, Chewable — reported in shortage by Sun Pharmaceutical Industries, Inc.. Therapeutic category: Psychiatry.
Presence of Foreign Tablets/Capsules — Recalling firm: Shire — Nationwide
